Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lyme Disease - Overview
Lyme Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease - Companies Involved in Therapeutics Development
Abzyme Therapeutics LLC
Agile Sciences Inc
Artes Biotechnology GmbH
Cortene Inc
Flightpath BioSciences Inc
Greffex Inc
Inovio Pharmaceuticals Inc
Ixodes AG
L2 Diagnostics LLC
NovoBiotic Pharmaceuticals LLC
Reven Pharmaceuticals Inc
Valneva SE
Lyme Disease - Drug Profiles
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azlocillin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Monoclol Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
disulfiram - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hygromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPOT-1003a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Mar 08, 2021: Valneva and Pfizer announce initiation of phase 2 study for Lyme disease vaccine candidate
Dec 02, 2020: Valneva announces acceleration of pediatric development for lyme disease vaccine candidate
Oct 20, 2020: Valneva announces positive initial results for second phase 2 study of Lyme disease vaccine candidate VLA15
Jul 22, 2020: Valneva announces positive initial results for phase 2 study of Lyme disease vaccine candidate
Sep 30, 2019: Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15
Jul 03, 2019: Valneva: Renowned Vaccinologist Dr. Stanley Plotkin to Present on VLA-15 at R&D Investor Day in New York City
Jul 01, 2019: Valneva initiates second phase 2 study for its Lyme Disease Vaccine Candidate VLA15
Jun 12, 2019: Valneva reports successful outcome of phase 2 run-in for its lyme disease vaccine candidate
Jun 11, 2019: Valneva to present Lyme Disease vaccine update at R&D Investor Day in New York City on July 9th
Apr 09, 2019: Valneva to present on Lyme vaccine candidate at the 19th World Vaccine Congress
Jan 31, 2019: VALNEVA reports positive initial booster data and fil phase 1 data for its lyme disease vaccine candidate
Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease
Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for lyme disease vaccine VLA15
Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate
Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Lyme Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Lyme Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Lyme Disease - Pipeline by Abzyme Therapeutics LLC, 2021
Lyme Disease - Pipeline by Agile Sciences Inc, 2021
Lyme Disease - Pipeline by Artes Biotechnology GmbH, 2021
Lyme Disease - Pipeline by Cortene Inc, 2021
Lyme Disease - Pipeline by Flightpath BioSciences Inc, 2021
Lyme Disease - Pipeline by Greffex Inc, 2021
Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, 2021
Lyme Disease - Pipeline by Ixodes AG, 2021
Lyme Disease - Pipeline by L2 Diagnostics LLC, 2021
Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
Lyme Disease - Pipeline by Reven Pharmaceuticals Inc, 2021
Lyme Disease - Pipeline by Valneva SE, 2021
Lyme Disease - Dormant Projects, 2021